Quantum Satissp. z o.o.

Other research and experimental development on natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2004-07-22
Share capital
60,000.00 PLN
Activity description

Quantum Satis Sp. z o.o. is a Warsaw-based CRO founded in 2004 that prepares and oversees Phase II–IV clinical trials in accordance with GCP. It also conducts observational studies and provides medical writing, data management and statistical analysis of results.

Registered address
ul. Białostocka 24/41, 03-741 Warszawa, Poland
Website
quantumsatis.pl
Email
Electronic delivery address
AE:PL-61062-70807-BIUJJ-25

Financials

Revenue history (in k)

Financial insight

  • The statement flags a going concern risk.

Filing timeliness

Financial statements were filed on time, on average 63 days early.

  • 202521/04/2026
  • 202408/04/2025
  • 202319/06/2024
  • 202204/07/2023
  • 202101/06/2022
  • 202021/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 82.35kMedianUSD 73.26kAverageUSD 3.23m
Net profit
This companyUSD -67.90kMedianUSD 69.70AverageUSD 82.18k
Operating costs
This companyUSD 140.71kMedianUSD 75.78kAverageUSD 3.04m
Assets
This companyUSD 109.23kMedianUSD 119.88kAverageUSD 3.90m

Industry

Offer

  • Clinical trial organization
  • Clinical trial management
  • Observational studies
  • Clinical trial monitoring
  • Medical writing
  • Clinical data management
  • Statistical analysis of studies
  • Clinical research training

Website technology

Website
  • WordPress
Analytics and marketing
  • Google Analytics

Public procurement

1 tender recorded as contractor, with a total value of $132,722.

SubjectAmount
28.2025 Monitoring and conduct of the non-commercial clinical study „Wieloośrodkowe, otwarte badanie kliniczne z eskalacją dawki mające na celu ocenę bezpieczeństwa terapii z zastosowaniem limfocytów o specyficznej aktywności przeciwwirusowej (VST) w leczeniu opornych, wirusowych zakażeń u pacjentów po allogenicznym przeszczepieniu hematopoetycznych komórek macierzystych (allovista).”
$132.7K

Authorized Representatives

Janusz Szczepanik – President of the Management Board

Manner of representation

Each member of the management board is authorised to make declarations on behalf of the company independently.

Ownership

OwnerSharesShare valueStake
Agnieszka Sinkiewiczage 30
20$2,701.2416.6667%
Agata Katarzyna Szczepanikage 50
20$2,701.2416.6667%
Janusz Szczepanikage 78
80$10,804.9766.6667%

Janusz Szczepanik and Agata Katarzyna Szczepanik hold a combined 83.3% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2004-09-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid for microenterprises in the form of public interventions concerning electricity, gas or heat supplies
$140
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$2,123
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$2,323

Competitors

Name
Care Access Polskasp. z o.o.
CCTSsp. z o.o.
TCIsp. z o.o.
Oncotarget Wojciech JurczakS.K.A.
Countess Laboratoriessp. z o.o.
Gcp-Service International Ltd. & Co. KgBranch (foreign co.)
Pharmaxi Polandsp. z o.o.
Clinbitsp. z o.o.
Medapp Clinical Researchsp. z o.o.
Biostat Research and Developmentsp. z o.o.

Change history

DateEvent
2023-09-07Share capital increase
2023-05-19PKD change
2019-01-10Address change
2007-08-02PKD change
2004-07-22Entered in the register

FAQ

Last updated: 2026-04-21